For the first time since last July the FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Thursday to evaluate two ...

Prostate cancer represents one of the most common malignancies in men in developed countries with increasing incidence in recent years due to the ...

Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...

Patients with benign prostatic hyperplasia (BPH) with preoperative overactive bladder (OAB) have higher postoperative storage ...

An international group of experts led by the Comprehensive Cancer Center (CCC) at MedUni Vienna and University Hospital ...

The National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-has published a new book explaining ...

Researchers at the University of British Columbia and BC Cancer have developed a new way to target proteins long considered ...

Nuclear medicine is being called a new frontier in cancer care, and new research shows potential new uses for it in treating ...

Investigators proposed criteria to define procedural success after minimally invasive surgical treatments (MISTs) for benign prostatic obstruction (BPO).

Free, comprehensive guidebook shows how prostate cancer screening has largely deemphasized invasive testing in order to avoid unnecessary procedures and treatment while at the same time saving ...

Free, comprehensive guidebook shows how prostate cancer screening has largely deemphasized invasive testing in order to avoid unnecessary procedures and treatment while at the same time saving lives.

Breakthroughs in identifying tumor biomarkers in liver, gastric, prostate, lung and other cancers and are accelerating ...